KRAS and neoplasm: It has been proposed that a metabolic shift in the canonical CMS2 tumors possibly due to KRAS mutations and copy number events results in CMS3 tumors whereas the stromal-enriched inflamed tumor microenvironment is the driver for the development of CMS4 tumors from the CMS2 subtype [5].